Patent ID: 11897968
Assignee: ALECTOR LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 1:
2. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs:5 and 40, respectively; SEQ ID NOs:6 and 41, respectively; SEQ ID NOs:7 and 42, respectively; SEQ ID NOs:8 and 43, respectively; SEQ ID NOs:9 and 44, respectively; SEQ ID NOs:10 and 45, respectively; SEQ ID NOs:11 and 46, respectively; SEQ ID NOs:12 and 47, respectively; SEQ ID NOs:13 and 48, respectively; SEQ ID NOs:14 and 49, respectively; SEQ ID NOs:15 and 50, respectively; SEQ ID NOs:16 and 51, respectively; SEQ ID NOs:17 and 52, respectively; SEQ ID NOs:18 and 53, respectively; SEQ ID NOs:19 and 54, respectively; SEQ ID NOs:20 and 55, respectively; SEQ ID NOs:21 and 56, respectively; SEQ ID NOs:22 and 57, respectively; SEQ ID NOs:23 and 58, respectively; SEQ ID NOs:24 and 59, respectively; SEQ ID NOs:25 and 60, respectively; SEQ ID NOs:26 and 61, respectively; SEQ ID NOs:27 and 62, respectively; SEQ ID NOs:28 and 63, respectively; SEQ ID NOs:29 and 64, respectively; SEQ ID NOs:30 and 65, respectively; SEQ ID NOs:31 and 66, respectively; SEQ ID NOs:32 and 67, respectively; SEQ ID NOs:33 and 68, respectively; SEQ ID NOs:34 and 69, respectively; SEQ ID NOs:35 and 70, respectively; SEQ ID NOs:36 and 71, respectively; SEQ ID NOs:37 and 72, respectively; SEQ ID NOs:38 and 73, respectively; and SEQ ID NOs:39 and 74, respectively; SEQ ID NOs:234 and 247, respectively; SEQ ID NOs:235 and 247, respectively; SEQ ID NOs:236 and 248, respectively; SEQ ID NOs:236 and 249, respectively; SEQ ID NOs:237 and 249, respectively; SEQ ID NOs:238 and 249, respectively; SEQ ID NOs:239 and 250, respectively; SEQ ID NOs:240 and 251, respectively; SEQ ID NOs:241 and 252, respectively; SEQ ID NOs:242 and 249, respectively; SEQ ID NOs:243 and 247, respectively; SEQ ID NOs:244 and 251, respectively; SEQ ID NOs:245 and 253, respectively; SEQ ID NOs:246 and 247, respectively; SEQ ID NOs:246 and 254, respectively; SEQ ID NOs:255 and 257, respectively; SEQ ID NOs:256 and 258, respectively; SEQ ID NOs:259 and 274, respectively; SEQ ID NOs:260 and 275, respectively; SEQ ID NOs:261 and 276, respectively; SEQ ID NOs:262 and 277, respectively; SEQ ID NOs:263 and 277, respectively; SEQ ID NOs:264 and 277, respectively; SEQ ID NOs:265 and 277, respectively; SEQ ID NOs:266 and 277, respectively; SEQ ID NOs:267 and 278, respectively; SEQ ID NOs:268 and 279, respectively; SEQ ID NOs:269 and 279, respectively; SEQ ID NOs:264 and 280, respectively; SEQ ID NOs:270 and 281, respectively; SEQ ID NOs:265 and 282, respectively; SEQ ID NOs:264 and 283, respectively; SEQ ID NOs:271 and 284, respectively; SEQ ID NOs:272 and 285, respectively; SEQ ID NOs:271 and 286, respectively; SEQ ID NOs:273 and 287, respectively; SEQ ID NOs:273 and 288, respectively; SEQ ID NOs:273 and 289, respectively; SEQ ID NOs:290 and 309, respectively; SEQ ID NOs:291 and 310, respectively; SEQ ID NOs:292 and 311, respectively SEQ ID NOs:293 and 312, respectively; SEQ ID NOs:294 and 313, respectively; SEQ ID NOs:295 and 314, respectively; SEQ ID NOs:296 and 315, respectively; SEQ ID NOs:290 and 316, respectively; SEQ ID NOs:297 and 317, respectively; SEQ ID NOs:298 and 318, respectively; SEQ ID NOs:292 and 319, respectively; SEQ ID NOs:299 and 320, respectively; SEQ ID NOs:300 and 311, respectively; SEQ ID NOs:301 and 321, respectively; SEQ ID NOs:302 and 322, respectively; SEQ ID NOs:303 and 311, respectively; SEQ ID NOs:304 and 322, respectively; SEQ ID NOs:305 and 322, respectively; SEQ ID NOs:301 and 323, respectively; SEQ ID NOs:301 and 324, respectively; SEQ ID NOs:301 and 325, respectively; SEQ ID NOs:306 and 326, respectively; SEQ ID NOs:307 and 327, respectively; or SEQ ID NOs:308 and 328, respectively.